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ABSTRACT
The activity of moxifloxacin was compared with
that of other antimicrobial agents against 54
strains of Ureaplasma spp., 54 strains of Myco-
plasma hominis, 14 strains of Mycoplasma genitali-
um, and 44 strains of Chlamydia trachomatis.
Moxifloxacin inhibited 90% of all isolates at a
concentration £1 mg ⁄L, being the most active
compound against C. trachomatis and sharing the
highest activity with garenoxacin and gemifloxa-
cin against mycoplasmas. Moxifloxacin killed the
30 mycoplasma isolates tested at a concentration
£1 mg ⁄L, except those resistant to fluoroquino-
lone. Thus, moxifloxacin has attracted interest as a
potential therapy for mycoplasmal or chlamydial
urogenital infections.
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The urogenital mycoplasmas Mycoplasma hominis,
M. genitalium and Ureaplasma spp., and Chlamydia
trachomatis, are involved in genitourinary
infections in men and women. The antibiotics
potentially active against mycoplasmas and
C. trachomatis are relatively low in number, and
include tetracyclines, macrolides and related anti-
biotics, and fluoroquinolones. Among fluoroqui-
nolones, the newer products, e.g. moxifloxacin,
have the highest in vitro activity against these
microorganisms. The activity of moxifloxacin
against human mycoplasmas [1–4] and C. tracho-
matis [5–7] has already been studied. These studies
concerned a relatively low number of isolates and
evaluated its bactericidal activity against myco-
plasmas for only three Ureaplasma spp. and two
M. hominis strains [4]. Our purpose was to extend
the study of the in vitro activity of moxifloxacin to a
larger number of strains of urogenital mycoplas-
mas, including M. genitalium and C. trachomatis,
in comparison with other fluoroquinolones—
ofloxacin against C. trachomatis; ofloxacin, and
levofloxacin, gatifloxacin, gemifloxacin and gare-
noxacin against mycoplasmas—and with other
antimicrobials, including erythromycin, azithro-
mycin and doxycycline. Moreover, the MBCs of
moxifloxacin for nine strains of Ureaplasma spp.,
seven strains of M. hominis and 14 strains of
M. genitalium were determined.
Fifty-four strains of Ureaplasma spp., one Urea-
plasma parvum and one U. urealyticum reference
strain, 30 doxycycline-susceptible clinical isolates
collected prospectively between 2003 and 2005,
and 22 doxycycline-resistant clinical isolates
collected prospectively between 1996 and 2005
at Pellegrin Hospital, Bordeaux, France, were
studied. For M. hominis, 54 strains were evaluated,
two reference strains, 32 doxycycline-susceptible
clinical isolates collected prospectively between
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2004 and 2005, and 20 doxycycline-resistant clinical
isolates collected prospectively between 2002 and
2005 in the same hospital. The 52 clinical isolates of
Ureaplasma spp. included 30 isolates of U. parvum
and 22 of U. urealyticum after species determina-
tion by real-time PCR [8]. Clinical isolates of
Ureaplasma spp. and M. hominis included two and
one genetically characterized fluoroquinolone-
resistant isolates, respectively. The quinolone
resistance-determining regions of the four topo-
isomerase genes were amplified and sequenced
for the three fluoroquinolone-resistant isolates,
as previously described [9]. The 14 strains of
M. genitalium included the seven genetically very
closely related ATCC reference strains (G37, M30,
R32G, TW 10-5, TW 10-6, TW 48-5 UTMB-10G),
five Danish clinical isolates (M2282, M2288, M2300,
M2321, M2341) [10] and two French clinical isolates
obtained, 6 weeks apart, from the same patient
(M6090 and M6151). Forty-four strains of C. tra-
chomatis, four reference strains belonging to sero-
vars D, E, F and H and 40 urogenital isolates
obtained between 1985 and 2004 at Pellegrin
Hospital, Bordeaux, France (seven isolated before
1990, 12 between 1990 and 1994, 12 between 1995
and 2000, and nine between 2001 and 2005) were
studied.
All antimicrobial powders tested were obtained
from their respective manufacturers and dissolved
according to recommendations. Susceptibility test-
ing was performed as previously described [11]
using an agar dilution method for mycoplasmal
strains and a broth dilution method for urea-
plasmal strains. MBCs of the different antimicro-
bials were determined, as previously reported
[4,11], for nine strains of Ureaplasma spp. (two
reference strains and seven clinical isolates, includ-
ing two with acquired resistance to fluoroquinol-
ones) and seven strains of M. hominis (two
reference strains and five clinical isolates, includ-
ing a fluoroquinolone-resistant one), and for the 14
strains of M. genitalium. Bactericidal activity was
identified as the MBC being no more than two
dilutions (four-fold) greater than the MIC [1,2].
Susceptibility testing of C. trachomatis was per-
formed on McCoy cells in 24-well microtitre plates,
with an inoculum of 104 inclusion-forming
units ⁄mL, as previously described [12,13].
Comparative in vitro activities of moxifloxacin
and other antimicrobials against 54 strains of
Ureaplasma spp. (31 U. parvum, 23 U. urealyticum),
54 strains of M. hominis, 14 strains of M. genitali-
um and 44 strains of C. trachomatis are shown in
Table 1. Doxycycline was the most potent mole-
cule, with an MIC90 of 0.25 mg ⁄L against doxy-
cycline-susceptible Ureaplasma spp. isolates,
whereas moxifloxacin, gemifloxacin and garenox-
acin were the most active against the doxycycline-
resistant isolates. Concerning M. hominis isolates,
moxifloxacin and gemifloxacin were the second
most potent molecules, with an MIC90 of
0.06 mg ⁄L, following garenoxacin (MIC90,
0.015 mg ⁄L) (Table 1). For both Ureaplasma spp.
and M. hominis, no significant MIC differences
Table 1. MIC ranges, MICs50 and MICs90 (mg ⁄L) of
moxifloxacin and other antimicrobials against 54 strains
of Ureaplasma spp., 54 strains of Mycoplasma hominis, 14
strains of M. genitalium and 44 strains of Chlamydia
trachomatis
Antimicrobials (no. of strains tested) MIC ranges MIC50 MIC90
Ureaplasma spp., doxycycline-susceptible (32)
Moxifloxacin 0.06–2 0.25 1
Ofloxacin 0.5–8 1 2
Levofloxacin 0.25–4 0.5 2
Gatifloxacin 0.25–2 0.5 1
Gemifloxacin 0.12–1 0.25 1
Garenoxacin 0.06–1 0.25 0.5
Doxycycline 0.03–0.5 0.12 0.25
Erythromycin 2–16 8 16
Ureaplasma spp., doxycycline-resistanta (22)
Moxifloxacin 0.12–1 0.25 1
Ofloxacin 1–8 2 2
Levofloxacin 0.5–8 1 2
Gatifloxacin 0.25–2 0.5 2
Gemifloxacin 0.12–1 0.5 1
Garenoxacin 0.06–1 0.25 1
Doxycycline 4 to >32 8 32
Erythromycin 1–8 4 8
M. hominis, doxycycline-susceptible (34)
Moxifloxacin 0.03–0.25 0.06 0.06
Ofloxacin 0.25–4 0.5 0.5
Levofloxacin 0.03–1 0.25 0.25
Gatifloxacin 0.03–0.25 0.06 0.12
Gemifloxacin 0.015–0.12 0.06 0.06
Garenoxacin 0.015–0.06 0.015 0.015
Doxycycline 0.06–0.12 0.06 0.12
Erythromycin >256 >256 >256
M. hominis, doxycycline-resistant (20)
Moxifloxacin 0.03–0.12 0.06 0.06
Ofloxacin 0.25–4 0.25 0.5
Levofloxacin 0.06–2 0.25 0.25
Gatifloxacin 0.03–0.25 0.06 0.12
Gemifloxacin 0.015–0.12 0.06 0.06
Garenoxacin 0.015–0.25 0.015 0.015
Doxycycline 2–8 4 4
Erythromycin >256 >256 >256
M. genitalium (14)
Moxifloxacin 0.03–0.06 0.06 0.12
Ofloxacin 1–2 1 2
Levofloxacin 0.5–1 0.5 1
Gatifloxacin 0.12–0.25 0.25 0.25
Gemifloxacin 0.12–0.25 0.25 0.25
Garenoxacin 0.12–0.25 0.12 0.25
Doxycycline 0.06–0.12 0.12 0.12
Erythromycin 0.007–0.015 0.007 0.015
C. trachomatis (44)
Moxifloxacin 0.015–0.12 0.03 0.06
Ofloxacin 0.25–4 1 2
Doxycycline 0.015–0.5 0.03 0.12
Azithromycin 0.015–0.5 0.12 0.25
Erythromycin 0.015–1 0.12 0.25
aEight of the 30 U. parvum and 14 of the 22 U. urealyticum clinical isolates were
doxycycline-resistant.
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were found between doxycycline-susceptible and
doxycycline-resistant isolates, except for doxy-
cycline. However, more doxycycline-resistant
isolates were obtained from U. urealyticum (14 of
22) than from U. parvum (eight of 30); this obser-
vation will have to be confirmed by studying
larger collections of strains. As compared with
previous studies testing Ureaplasma spp. and
M. hominis isolates obtained before 2000 [1–4], in
which different methodologies were used, our
results using more recent isolates were not sig-
nificantly different from those obtained for fluor-
oquinolones, with the MIC90 of moxifloxacin
ranging from 0.25 to 1 mg ⁄L for Ureaplasma spp.
and from 0.03 to 0.12 mg ⁄L for M. hominis,
depending on the study.
Against M. genitalium, erythromycin was the
most active molecule, with an MIC90 of
0.015 mg ⁄L. After erythromycin, moxifloxacin
and doxycycline had similar activity, with MIC90s
of 0.12 mg ⁄L, followed by the three other newer
quinolones, garenoxacin, gemifloxacin and gati-
floxacin, confirming our previous data obtained
with reference strains [2,4]. The sole study includ-
ing a larger number of M. genitalium strains, which
were genetically different from the present one
[10], showed similar results, with moxifloxacin
having the highest activity (MICs, 0.03–0.5 mg ⁄L)
among fluoroquinolones. It should be noted that
the seven very closely related ATCC strains had
some discrepancies, especially concerning the
MBC values of gatifloxacin (MBCs ranging from
0.25 to 4 mg ⁄L) and doxycycline (MBCs ranging
from 0.12 to 1 mg ⁄L) (Table 2), highlighting the
reproducibility limits of the broth dilution method
used to determine MBCs, at least of these two
antibiotics.
As previously described [5,7], moxifloxacin
inhibited 90% of C. trachomatis isolates at a value
of 0.06 mg ⁄L. It was the most potent antibiotic,
Table 2. MBCs (mg ⁄L) of moxifloxacin and other antimicrobials against nine strains of Ureaplasma spp., seven strains of
Mycoplasma hominis, and 14 strains of M. genitalium
Strain and
antibiotic
Moxifloxacin Ofloxacin Levofloxacin Gatifloxacin Gemifloxacin Garenoxacin Doxycycline Erythromycin
MICa MBCa Rb MIC MBC R MIC MBC R MIC MBC R MIC MBC R MIC MBC R MIC MBC R MIC MBC R
U. parvum
Type strain 0.25 0.5 2 2 2 1 2 1 0.5 1 1 1 0.5 1 2 0.5 0.5 1 –c – – – – –
3775 0.25 0.5 2 1 4 4 2 4 2 0.5 2 4 0.5 1 2 0.25 0.5 2 – – – – – –
3904 0.25 0.25 1 0.5 2 4 0.25 2 8 0.25 0.5 2 0.12 0.5 4 0.12 4 32 – – – – – –
3920 0.25 0.5 2 1 2 2 0.5 2 4 0.25 2 8 0.5 1 2 0.25 0.5 2 – – – – – –
U. urealyticum
Type strain 0.25 0.5 2 2 2 1 2 2 1 0.5 2 4 0.5 0.5 1 0.25 4 16 – – – – – –
3879 0.25 0.5 2 1 4 4 2 4 2 0.5 1 2 0.5 1 2 0.12 0.5 4 – – – – – –
3899 0.25 0.25 1 1 4 4 0.5 1 2 0.5 1 2 0.25 0.5 2 0.06 2 32 – – – – – –
3868d 0.5 4 8 2 16 8 0.5 4 8 1 8 8 0.5 4 8 0.25 4 16 – – – – – –
3898d 1 8 8 2 16 8 1 8 8 1 8 8 1 8 8 0.5 4 8 – – – – – –
M. hominis
PG21 0.06 0.12 2 1 8 8 0.5 4 8 0.12 0.25 2 0.06 0.25 4 £0.015 0.5 32 – – – – – –
M132 0.06 0.12 2 1 2 2 0.25 4 16 0.06 0.25 4 0.06 0.12 2 £0.015 0.25 16 – – – – – –
3903 0.06 0.12 2 1 1 1 0.25 0.5 2 0.06 0.5 8 0.03 0.25 8 £0.015 0.015 1 – – – – – –
3901 0.06 0.12 2 1 2 2 0.25 0.5 2 0.12 0.12 1 0.06 0.25 4 £0.015 0.12 8 – – – – – –
3893 0.06 0.12 2 1 2 2 0.5 1 2 0.12 0.5 2 0.06 0.25 4 0.015 0.03 2 – – – – – –
3717 0.06 0.12 2 1 2 2 0.5 2 4 0.12 0.5 4 0.03 0.25 8 0.015 0.25 16 – – – – – –
3525e 0.25 4 16 4 32 8 1 8 8 0.5 4 8 0.12 4 33 0.06 2 33 – – – – – –
M. genitalium
G37 0.06 0.06 1 2 2 1 1 1 1 0.25 0.5 2 0.25 0.5 2 0.12 0.25 2 0.12 0.12 1 0.007 0.007 1
M30 0.03 0.06 2 1 4 4 1 1 1 0.12 0.25 2 0.12 0.5 4 0.06 0.12 2 0.03 0.12 4 0.0035 0.007 2
R32G 0.03 0.12 4 1 2 2 1 2 2 0.25 0.5 2 0.25 0.5 2 0.06 0.12 2 0.06 0.25 4 0.007 0.015 2
TW 10-5 0.12 0.25 2 2 4 2 1 4 4 0.25 1 4 0.25 0.5 2 0.25 0.25 1 0.06 1 16 0.007 0.03 4
TW 10-6 0.06 0.25 4 2 4 2 1 2 2 0.25 4 1 0.25 0.5 2 0.12 0.25 2 0.12 1 4 0.0035 0.015 4
TW 48-5 0.06 0.12 2 2 4 2 1 2 2 0.25 0.5 2 0.25 0.5 2 0.12 0.25 2 0.12 0.5 4 0.0035 0.007 2
UTMB-10G 0.03 0.06 2 1 4 4 1 2 2 0.25 0.5 2 0.25 0.5 2 0.06 0.12 2 0.06 0.12 2 0.0035 0.007 2
M2282 0.06 0.12 2 2 2 1 1 2 2 0.12 0.5 4 0.25 1 4 0.12 0.5 4 0.06 0.5 8 0.007 0.03 4
M2288 0.06 0.12 2 2 2 1 2 4 2 0.5 1 2 0.5 1 2 0.12 0.5 4 0.12 1 8 0.007 0.015 2
M2300 0.03 0.06 2 2 4 2 0.5 1 2 0.5 1 2 0.25 0.5 2 0.12 0.12 1 0.06 0.12 2 0.0035 0.007 2
M2321 0.06 0.12 2 2 4 2 1 2 2 0.25 0.5 2 0.12 0.25 2 0.06 0.25 4 0.12 0.5 4 0.0035 0.007 2
M2341 0.06 0.06 1 2 2 1 1 1 1 0.12 0.25 2 0.06 0.25 4 0.06 0.06 1 0.25 2 8 0.007 0.015 2
M6151 0.03 0.06 2 1 2 2 1 4 4 0.12 0.25 2 0.25 0.5 2 0.06 0.12 2 0.03 0.12 4 0.007 0.015 2
M6090 0.06 0.06 1 2 4 2 1 2 2 0.25 0.5 2 0.25 0.5 2 0.12 0.12 1 0.12 0.5 4 0.007 0.03 4
aMBCs (mg ⁄L) determined by the method described in the Materials and methods section; MICs (mg ⁄L) determined by the broth dilution method in the same experiment as
the MBCs.
bR, MBC ⁄MIC ratio; when the ratio value was £4, the drug was considered to be bactericidal.
cNot determined.
dU. urealyticum isolates with acquired fluoroquinolone resistance with mutations in quinolone resistance-determining regions of GyrA (D95E) and ParC (Y57H, A123T, and
A124T) (Escherichia coli numbering).
eIsolate with acquired fluoroquinolone resistance with mutations in the ParC quinolone resistance-determining region (S80I, A143V) (E. coli numbering).
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followed by doxycycline and both macrolides.
Interestingly, no significant difference in the
susceptibility profile of strains was noticed over
the past 20 years (data not shown).
MBCs of moxifloxacin and other antimicrobials
against nine strains of Ureaplasma spp., seven
strains ofM. hominis and 14 strains ofM. genitalium
are presented in Table 2. Except for three isolates
identified during this study, Ureaplasma spp. 3868
and 3898, belonging to the U. urealyticum species,
and M. hominis 3525, which acquired resistance to
fluoroquinolones, the MBCs of moxifloxacin
against Ureaplasma spp. and M. hominis ranged
from 0.12 to 0.5 mg ⁄L. All the moxifloxacin MBCs
were less than or equal to four times the MICs
found during the same experiment (MBC ⁄MIC
ratio, R £4, Table 2), indicating bactericidal activ-
ity. Although moxifloxacin kept its activity against
the three fluoroquinolone-resistant isolates
harbouring gyrA and ⁄ or parCmutations with MICs
£1 mg ⁄L (Table 2), the fluoroquinolone was no
longer bactericidal in vitro, with an MBC ⁄MIC
ratio of 8. It should be noted that, for these isolates,
none of the studied fluoroquinolones seemed to
be bactericidal in spite of relatively low
corresponding MICs, ranging from 0.25 to
4 mg ⁄L (Table 2).
For the 14 M. genitalium strains studied, the
MBCs of moxifloxacin ranged from 0.06 to
0.25 mg ⁄L, with an MBC90 value of 0.25 mg ⁄L
and an MBC ⁄MIC ratio £4 (Table 2), showing the
highest bactericidal activity among fluoroquino-
lones. The lowest MBCs against M. genitalium
isolates were obtained with erythromycin
(MBC90, 0.03 mg ⁄L). Although doxycycline was
bactericidal in vitro against ten of the 14 M. gen-
italium strains studied, the obvious discrepancy
between its in vitro and in vivo activities against
M. genitalium should be mentioned, as treatment
failures after doxycycline therapy have been
commonly reported in clinical studies of M. gen-
italium non-gonococcal urethritis [14].
In summary, this study confirms the high
in vitro activity of moxifloxacin against recent
isolates of urogenital mycoplasmas and against a
significant number of C. trachomatis isolates. Fur-
thermore, the new data on its bactericidal activity
against urogenital mycoplasmas show that moxi-
floxacin is bactericidal in vitro against all the
mycoplasma and ureaplasma isolates, except
those resistant to fluoroquinolones. Thus, moxi-
floxacin has attracted interest as a potential
therapy for mycoplasmal or chlamydial urogen-
ital infections, all the more because it has recently
resolved azithromycin-resistant M. genitalium
non-gonococcal urethritis in men following treat-
ment failure with azithromycin [14].
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ABSTRACT
The pathological consequences of exposure to the
vaccine strain Brucella abortus S19 were evaluated
in 30 employees from vaccine-manufacturing
plants. Active brucellosis was diagnosed in 21
subjects, of whom only five recalled an accidental
exposure. Clinical manifestations were mild, and
only one patient presented a complication. After
antimicrobial therapy, initially symptomatic
patients either experienced clinical remission or
had mild persistent symptoms. This is the first
study reporting infection by B. abortus S19 among
workers from vaccine-manufacturing plants,
which in many cases was acquired from unnoticed
exposures. Measures to improve the safety of
B. abortus S19 handling should be implemented.
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Brucellosis, a zoonotic disease caused by different
species of Brucella, affects several regions, includ-
ing South America. Humans usually become
infected by contact with tissues or secretions from
cattle (Brucella abortus), goats and sheep (B. melit-
ensis), pigs (B. suis) and dogs (B. canis). Clinical
manifestations of human brucellosis range from
asymptomatic to acute disease, complicated
chronic disease or, occasionally, death.
The attenuated strain B. abortus S19 has been
the vaccine most widely used to prevent bovine
brucellosis. In some regions, this vaccine has been
replaced by the RB51 strain, a rough mutant that
is less virulent for cattle and does not interfere
with serological screening [1]. In spite of their
reduced virulence, both vaccines can be patho-
genic for humans, as has also been observed for
B. melitensis Rev-1 [2]. Infection due to these
vaccines is usually acquired from conjunctival
splashes, skin cuts or, occasionally, infectious
aerosols, and generally occurs in individuals
involved in animal vaccination [3–6]. An outbreak
of brucellosis among employees of a laboratory
manufacturing the Rev-1 vaccine has also been
reported [7]. In contrast, there are no reports of
human brucellosis due to S19 or RB51 strains
acquired within vaccine production plants.
The goal of this study was to analyze the clinical,
epidemiological and diagnostic aspects of workers
with potential exposure to B. abortus S19 in labora-
tories producing the S19 vaccine in Argentina.
Thirty employees from S19-manufacturing
plants (age 19–62 years, mean ± SD 33.5 ± 13.19
years, 20 males) were studied. They were referred
between February 1999 and June 2006 because they
had suggestive symptoms and ⁄ or serology posi-
tive for brucellosis. The clinical records of these
individuals were retrospectively analyzed. Indi-
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